Research from industry analyst GlobalData underscores the uncertainty surrounding the prospects for Aduhelm (aducanumab), the newly-approved Alzheimer’s med from Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523).
In a much-anticipated decision, announced this week, the US Centers for Medicare & Medicaid Services (CMS) opted not to offer broad coverage of the therapy to Medicare recipients.
Patients will be able to gain access to the treatment only if they are enrolled in a clinical trial, an outcome which severely limits the number of eligible recipients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze